$TELO

Telomir Pharmaceuticals, Inc. (TELO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Telomir Pharmaceuticals, Inc. (TELO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Consulting Agreement This Consulting Agreement (this “Agreement”) is entered into as of June 6, 2026 (“Effective Date”) by and between Telomir Pharmaceuticals, Inc. (“Company”) and Andriy Mushak (“Consultant”). Company and Consultant may

Original reporting
Published Jun 8, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$TELO
Neutral
medium confidence
Mentioned
$TELO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TELONeutralLow
01

Why it matters

This may reduce execution risk around reporting and audit processes, but it does not provide new operational milestones, trial results, or funding terms.

02

Market read

A governance/finance-operations update with limited direct trading implications unless it precedes a financing or major corporate action.

03

What to watch

Traders may watch for follow-on 8-Ks/financing announcements; this document alone is not a catalyst.

Relevance 6/10Novelty 4/10Timing: Filed June 8, 2026 (after-hours/EDGAR)

Background

The 8-K Item 5.02 attaches a consulting agreement for a fractional CFO role focused on SEC compliance, audit readiness, internal controls, and capital-markets support.

Company-level read

Ticker impact

$TELONeutralMedium confidence
Context

Telomir Pharmaceuticals disclosed an 8-K Item 5.02 appointing a fractional CFO consultant under a new consulting agreement.

Expected impact

Likely limited near-term impact; any effect would be indirect via improved SEC/audit readiness and capital-markets support.

Evidence & confidence

The agreement details scope and $6,000/month compensation but does not disclose new clinical, regulatory, financing, or commercial outcomes.

Market effects

Minimal; fractional CFO/SEC readiness arrangements are not a sector-wide signal.

None indicated.

None indicated.

Counterpoint

The appointment could signal internal capacity constraints or upcoming financing/transaction work, but the filing itself does not confirm that.

Key entities

  • Telomir Pharmaceuticals, Inc.

    Company filing the 8-K and entering the fractional CFO consulting agreement.

  • Andriy Mushak

    Fractional CFO consultant engaged for SEC reporting oversight and related finance services.

Related articles

$AONMedAI 9/10

Aon plc (AON): Other Events

Aon plc (AON) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 14, 2026, Aon North America, Inc., a Delaware corporation (“ANA”), Aon Global Holdings plc, a public limited company formed under the laws of England and Wales (“AGH” and, together with ANA, the “Issuers”), Aon plc, an Irish public limited com

$CICBMed

CION Investment Corp (CICB): Other Events

CION Investment Corp (CICB) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 17, 2026, CĪON Investment Corporation (“CION”) entered into an Amended and Restated Limited Liability Company Agreement (the “LLC Agreement”) of Senior Loan Fund Partners, LLC (the “Joint Venture”), a newly formed Delaware limited liability c